Submitted by Anonymous (not verified) on 28 November 2023 - 11:17
Human medicines European public assessment report (EPAR): Tecartus, Brexucabtagene autoleucel, Lymphoma, Mantle-Cell, Date of authorisation: 14/12/2020, Revision: 5, Status: Authorised
Source: